Summary:
EFC15804 is a clinical research study to determine if the study medication can reduce the rate of moderate to severe acute exacerbations of COPD, over a maximum of one year of treatment. The study medication (one not yet approved by the health authority)
called Dupilumab is an injectable medication as opposed to the most commonly used COPD medications which are inhalers. The clinical research study will also evaluate if the study medication helps to improve the way patients feel, their level of activity and breathe, which may potentially reduce the need for rescue or reliever medications. Patients on this study will receive either Dupilumab or placebo. Placebo is an inactive solution that does not contain medication. Study medications and/or placebo will be injected under the skin (“subcutaneously”) once every 2 weeks. You have a 1 in 2 (or 50%) chance of receiving placebo only, on this study. You will continue taking your background therapy while on the study.
- Have COPD
- Be 40 - 80 years old
- Be a current or former smoker
- Had exacerbation (flare up of COPD) during the last year needing either hospital admission or steroid treatment
- Currently being treated with established inhaled long-acting beta2 adrenergic agonist [called LABA], long-acting muscarinic antagonist [called LAMA] and inhaled corticosteroid background therapy [called ICS] (triple therapy) or if ICS is contraindicated with LABA and LAMA (double therapy).
Qualified Participants May Receive:
Assessment of their COPd and close follow up, study medications and compensation for their time and travel.